RecruitingPhase 3NCT05645107
A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma
Studying OBSOLETE: Other immunodeficiency syndrome with predominantly antibody defects
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Grifols Therapeutics LLC
- Intervention
- Xembify(drug)
- Enrollment
- 386 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2022 – 2026
Study locations (30)
- GC2202 Study Site 103, St. Petersburg, Florida, United States
- GC2202 Study Site 111, Bethesda, Maryland, United States
- GC2202 Study Site 109, Greenville, North Carolina, United States
- GC2202 Decentralized Study Site 114, Morrisville, North Carolina, United States
- GC2202 Study Site 105, Canton, Ohio, United States
- GC2202 Study Site 110, Rockville, South Carolina, United States
- GC2202 Study Site 702, Banja Luka, Bosnia and Herzegovina
- GC2202 Study Site 703, Mostar, Bosnia and Herzegovina
- GC2202 Study Site 701, Sarajevo, Bosnia and Herzegovina
- GC2202 Study Site 202, Burgas, Bulgaria
- GC2202 Study Site 203, Plovdiv, Bulgaria
- GC2202 Study Site 210, Plovdiv, Bulgaria
- GC2202 Study Site 205, Rousse, Bulgaria
- GC2202 Study Site 209, Sofia, Bulgaria
- GC2202 Study Site 201, Sofia, Bulgaria
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05645107 on ClinicalTrials.govOther trials for OBSOLETE: Other immunodeficiency syndrome with predominantly antibody defects
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2, PHASE3NCT05678621Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy: Immunoglobulin Stopping or ExtensionMonash University
- RECRUITINGNCT00001244Immune Regulation in Patients With Common Variable Immunodeficiency and Related Inborn Errors of Immunity (IEI)National Institute of Allergy and Infectious Diseases (NIAID)
See all trials for OBSOLETE: Other immunodeficiency syndrome with predominantly antibody defects →